NovoCure
NVCR
58 hedge funds and large institutions have $196M invested in NovoCure in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 8 closing their positions.
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
119% more call options, than puts
Call options by funds: $3.03M | Put options by funds: $1.38M
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
23% more funds holding
Funds holding: 47 → 58 (+11)
21% less capital invested
Capital invested by funds: $249M → $196M (-$52.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StepStone Group
La Jolla,
California
|
+$26.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.99M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.65M |
| 4 |
HCM
Highline Capital Management
New York
|
+$1.57M |
| 5 |
RCM
Riverhead Capital Management
Wilmington,
Delaware
|
+$825K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$2.56M |
| 2 |
Morgan Stanley
New York
|
-$2.38M |
| 3 |
CCM
Century Capital Management
Boston,
Massachusetts
|
-$1.48M |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$807K |
| 5 |
Two Sigma Investments
New York
|
-$639K |
NVCR Hedge Fund Activity: Q1 2016 in Review
58 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2016, worth a combined $196M — down 21% from $249M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NVCR positions and 8 closed out — a net gain of 11 holders — while 19 added to existing stakes and 14 trimmed.
The largest buyer was StepStone Group, opening a new position worth an estimated $26.1M. The largest seller was Alkeon Capital Management, cutting an estimated $2.56M.
- 58 institutional investors held NovoCure (NVCR) as of Q1 2016, up from 47 in Q4 2015.
- Funds reported $196M of NovoCure stock for Q1 2016, down 21% quarter-over-quarter.
- 19 funds opened new NovoCure positions in Q1 2016 and 8 closed out, a net change of +11 holders.
- The largest NovoCure buyer in Q1 2016 was StepStone Group, an estimated $26.1M added.
- The largest NovoCure seller in Q1 2016 was Alkeon Capital Management, an estimated $2.56M sold.
Based on aggregated 13F filings for Q1 2016.